Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles

Brian T. Helfand, Stacy Loeb, John Cashy, Joshua J. Meeks, C. Shad Thaxton, Misop Han, William J. Catalona

Research output: Contribution to journalArticle

Abstract

Purpose: In collaboration with deCODE Genetics Inc. we previously reported on the association between genetic variants on chromosome 8q24 and prostate cancer susceptibility. Several prior studies have examined the relationship between these 8q24 alleles and clinical tumor features. In this study we examine the differences in clinical and pathological tumor features between carriers and noncarriers of these 8q24 alleles in patients with prostate cancer. Materials and Methods: We genotyped 551 white men who underwent radical prostatectomy or radiation therapy for clinically localized prostate cancer at single institution between 2002 and 2005. Of these men 177 (32.1%) were carriers of the -8 allele of the microsatellite marker DG8S737, the A allele of the single nucleotide polymorphism rs1447295 and/or the A allele of the rs16901979 (a surrogate single nucleotide polymorphism of HapC) 8q24 alleles. We used statistical analyses to compare the distribution of clinical characteristics and pathological outcomes between carriers and noncarriers. Results: The -8, A and HapC surrogate single nucleotide polymorphism alleles were present in 77 (14%), 128 (23%) and 61 (14%) patients with prostate cancer, respectively. Carriers of the -8 or multiple 8q24 alleles were significantly more likely to have a Gleason score of 7 or greater and lymph node metastases. Among men with a family history of prostate cancer, carriers of the -8 allele had a significantly greater risk of high grade disease (64% vs 39%, p = 0.04). Conclusions: In our predominantly surgically treated population there was a significant association between 8q24 prostate cancer susceptibility alleles, particularly the -8 allele, and high grade disease. In men with a family history of prostate cancer the presence of 1 or more of these alleles also conferred a greater risk of some adverse pathological features.

Original languageEnglish (US)
Pages (from-to)2197-2202
Number of pages6
JournalJournal of Urology
Volume179
Issue number6
DOIs
StatePublished - Jun 2008

Fingerprint

Prostatic Neoplasms
Alleles
Neoplasms
Single Nucleotide Polymorphism
Hospital Distribution Systems
Neoplasm Grading
Prostatectomy
Microsatellite Repeats
Radiotherapy
Chromosomes
Lymph Nodes
Neoplasm Metastasis

Keywords

  • disease susceptibility
  • genes
  • genetics
  • myc
  • prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles. / Helfand, Brian T.; Loeb, Stacy; Cashy, John; Meeks, Joshua J.; Thaxton, C. Shad; Han, Misop; Catalona, William J.

In: Journal of Urology, Vol. 179, No. 6, 06.2008, p. 2197-2202.

Research output: Contribution to journalArticle

Helfand, Brian T. ; Loeb, Stacy ; Cashy, John ; Meeks, Joshua J. ; Thaxton, C. Shad ; Han, Misop ; Catalona, William J. / Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles. In: Journal of Urology. 2008 ; Vol. 179, No. 6. pp. 2197-2202.
@article{445821633a4a4711bfe835e8ee5b7db7,
title = "Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles",
abstract = "Purpose: In collaboration with deCODE Genetics Inc. we previously reported on the association between genetic variants on chromosome 8q24 and prostate cancer susceptibility. Several prior studies have examined the relationship between these 8q24 alleles and clinical tumor features. In this study we examine the differences in clinical and pathological tumor features between carriers and noncarriers of these 8q24 alleles in patients with prostate cancer. Materials and Methods: We genotyped 551 white men who underwent radical prostatectomy or radiation therapy for clinically localized prostate cancer at single institution between 2002 and 2005. Of these men 177 (32.1{\%}) were carriers of the -8 allele of the microsatellite marker DG8S737, the A allele of the single nucleotide polymorphism rs1447295 and/or the A allele of the rs16901979 (a surrogate single nucleotide polymorphism of HapC) 8q24 alleles. We used statistical analyses to compare the distribution of clinical characteristics and pathological outcomes between carriers and noncarriers. Results: The -8, A and HapC surrogate single nucleotide polymorphism alleles were present in 77 (14{\%}), 128 (23{\%}) and 61 (14{\%}) patients with prostate cancer, respectively. Carriers of the -8 or multiple 8q24 alleles were significantly more likely to have a Gleason score of 7 or greater and lymph node metastases. Among men with a family history of prostate cancer, carriers of the -8 allele had a significantly greater risk of high grade disease (64{\%} vs 39{\%}, p = 0.04). Conclusions: In our predominantly surgically treated population there was a significant association between 8q24 prostate cancer susceptibility alleles, particularly the -8 allele, and high grade disease. In men with a family history of prostate cancer the presence of 1 or more of these alleles also conferred a greater risk of some adverse pathological features.",
keywords = "disease susceptibility, genes, genetics, myc, prostatic neoplasms",
author = "Helfand, {Brian T.} and Stacy Loeb and John Cashy and Meeks, {Joshua J.} and Thaxton, {C. Shad} and Misop Han and Catalona, {William J.}",
year = "2008",
month = "6",
doi = "10.1016/j.juro.2008.01.110",
language = "English (US)",
volume = "179",
pages = "2197--2202",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles

AU - Helfand, Brian T.

AU - Loeb, Stacy

AU - Cashy, John

AU - Meeks, Joshua J.

AU - Thaxton, C. Shad

AU - Han, Misop

AU - Catalona, William J.

PY - 2008/6

Y1 - 2008/6

N2 - Purpose: In collaboration with deCODE Genetics Inc. we previously reported on the association between genetic variants on chromosome 8q24 and prostate cancer susceptibility. Several prior studies have examined the relationship between these 8q24 alleles and clinical tumor features. In this study we examine the differences in clinical and pathological tumor features between carriers and noncarriers of these 8q24 alleles in patients with prostate cancer. Materials and Methods: We genotyped 551 white men who underwent radical prostatectomy or radiation therapy for clinically localized prostate cancer at single institution between 2002 and 2005. Of these men 177 (32.1%) were carriers of the -8 allele of the microsatellite marker DG8S737, the A allele of the single nucleotide polymorphism rs1447295 and/or the A allele of the rs16901979 (a surrogate single nucleotide polymorphism of HapC) 8q24 alleles. We used statistical analyses to compare the distribution of clinical characteristics and pathological outcomes between carriers and noncarriers. Results: The -8, A and HapC surrogate single nucleotide polymorphism alleles were present in 77 (14%), 128 (23%) and 61 (14%) patients with prostate cancer, respectively. Carriers of the -8 or multiple 8q24 alleles were significantly more likely to have a Gleason score of 7 or greater and lymph node metastases. Among men with a family history of prostate cancer, carriers of the -8 allele had a significantly greater risk of high grade disease (64% vs 39%, p = 0.04). Conclusions: In our predominantly surgically treated population there was a significant association between 8q24 prostate cancer susceptibility alleles, particularly the -8 allele, and high grade disease. In men with a family history of prostate cancer the presence of 1 or more of these alleles also conferred a greater risk of some adverse pathological features.

AB - Purpose: In collaboration with deCODE Genetics Inc. we previously reported on the association between genetic variants on chromosome 8q24 and prostate cancer susceptibility. Several prior studies have examined the relationship between these 8q24 alleles and clinical tumor features. In this study we examine the differences in clinical and pathological tumor features between carriers and noncarriers of these 8q24 alleles in patients with prostate cancer. Materials and Methods: We genotyped 551 white men who underwent radical prostatectomy or radiation therapy for clinically localized prostate cancer at single institution between 2002 and 2005. Of these men 177 (32.1%) were carriers of the -8 allele of the microsatellite marker DG8S737, the A allele of the single nucleotide polymorphism rs1447295 and/or the A allele of the rs16901979 (a surrogate single nucleotide polymorphism of HapC) 8q24 alleles. We used statistical analyses to compare the distribution of clinical characteristics and pathological outcomes between carriers and noncarriers. Results: The -8, A and HapC surrogate single nucleotide polymorphism alleles were present in 77 (14%), 128 (23%) and 61 (14%) patients with prostate cancer, respectively. Carriers of the -8 or multiple 8q24 alleles were significantly more likely to have a Gleason score of 7 or greater and lymph node metastases. Among men with a family history of prostate cancer, carriers of the -8 allele had a significantly greater risk of high grade disease (64% vs 39%, p = 0.04). Conclusions: In our predominantly surgically treated population there was a significant association between 8q24 prostate cancer susceptibility alleles, particularly the -8 allele, and high grade disease. In men with a family history of prostate cancer the presence of 1 or more of these alleles also conferred a greater risk of some adverse pathological features.

KW - disease susceptibility

KW - genes

KW - genetics

KW - myc

KW - prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=43049114534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049114534&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2008.01.110

DO - 10.1016/j.juro.2008.01.110

M3 - Article

C2 - 18423739

AN - SCOPUS:43049114534

VL - 179

SP - 2197

EP - 2202

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -